PK/PD of Oxazolidinones
Author:
Theuretzbacher Ursula
Publisher
Springer New York
Reference192 articles.
1. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P et al (2008) Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 31(2):122–129
2. Alffenaar JWC, Kosterink JGW, Altena R, van der Werf TS, Uges DRA, Proost JH (2010) Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32(1):97–101
3. Allen GP, Bierman BC (2009) In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium. Int J Antimicrob Agents 34(1):21–24
4. Allen GP, Deshpande LM (2010) Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 35(1):45–49
5. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A et al (2007) pharmacokinetics/pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44(1):79–86